Effect of Nusinersen on Respiratory and Bulbar Function in Children with Spinal Muscular Atrophy: Real-World Experience from a Single Center

Abstract

Background Due to the limited data from clinical trials and real-world settings in the realm of nusinersen, there is a need for further evidence. This study seeks to assess the impact of nusinersen, when combined with standard care, on bulbar function, respiratory function, and the necessity for respiratory support among pediatric patients with spinal muscular atrophy (SMA).

Methods Prospective observational study, involving pediatric SMA patients (Types 1–3) undergoing nusinersen treatment at the Hospital Universitario Virgen del Rocío in Spain over at least 24 months. The cohort included 11 SMA type 1 patients, comprising 6 type 1b and 5 type 1c, 12 SMA type 2 patients, and 5 SMA type 3 patients.

Results Twenty-eight pediatric patients were enrolled with the majority being male (n = 20). Patients with type 1 were diagnosed and received treatment significantly earlier than those with types 2 and 3 (p < 0.001). Additionally, there was a longer period between diagnosis and the start of treatment in types 2 and 3 (p = 0.002). Follow-up revealed statistically improved functional and respiratory outcomes associated with earlier initiation of nusinersen treatment at 6, 12, and 24 months in all phenotypes. The ability to swallow and feed correctly remained unchanged throughout the study, with SMA type 1c patients maintaining oral feeding in contrast to patients with SMA type 1b. Notably, no deaths were recorded.

Conclusions This study provides important insights into the real-world clinical progress of pediatric SMA patients and their response to nusinersen treatment, highlighting the significance of early intervention for better functional and respiratory outcomes.

Keywords

spinal muscular atrophy - children - nusinersen - respiratory function - bulbar function

Publikationsverlauf

Eingereicht: 24. April 2024

Angenommen: 01. August 2024

Accepted Manuscript online:
05. August 2024

Artikel online veröffentlicht:
30. August 2024

• References

• 1 Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015; 33 (04) 831-846 eng.
• 2 Al Dakhoul S. Very severe spinal muscular atrophy (Type 0). Avicenna J Med 2017; 7 (01) 32-33 eng.
• 3 Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers 2022; 8 (01) 52
• 4 Farrar MA, Vucic S, Johnston HM, du Sart D, Kiernan MC. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr 2013; 162 (01) 155-159
• 5 D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis 2011; 6: 71
• 6 Neil EE, Bisaccia EK. Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther 2019; 24 (03) 194-203
• 7 Blonda A, Barcina Lacosta T, Toumi M, Simoens S. Assessing the value of nusinersen for spinal muscular atrophy: a comparative analysis of reimbursement submission and appraisal in European countries. Front Pharmacol 2022; 12: 750742
• 8 Pechmann A, Langer T, Schorling D. et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the Expanded Access Program in Germany. J Neuromuscul Dis 2018; 5 (02) 135-143 eng.
• 9 Finkel RS, Mercuri E, Darras BT. et al. ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1723-1732
• 10 Hepkaya E, Kılınç Sakallı AA, Ülkersoy İ. et al. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy. Pediatr Int 2022; 64 (01) e15310
• 11 Gómez-García de la Banda M, Amaddeo A, Khirani S. et al. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. Pediatr Pulmonol 2021; 56 (01) 299-306
• 12 Pane M, Coratti G, Sansone VA. et al. Italian EAP Working Group. Type I SMA “new natural history”: long-term data in nusinersen-treated patients. Ann Clin Transl Neurol 2021; 8 (03) 548-557
• 13 Audic F, de la Banda MGG, Bernoux D. et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis 2020; 15 (01) 148
• 14 Ergenekon AP, Yilmaz Yegit C, Cenk M. et al. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen. Pediatr Int 2022; 64 (01) e15175 eng.
• 15 Scheijmans FEV, Cuppen I, van Eijk RPA. et al. Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study. Brain Commun 2022; 4 (06) fcac269
• 16 Sansone VA, Pirola A, Albamonte E. et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen. J Pediatr 2020; 219: 223-228.e4
• 17 Osredkar D, Jílková M, Butenko T. et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol 2021; 30: 1-8
• 18 Pechmann A, Behrens M, Dörnbrack K. et al. SMArtCARE Study Group. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain 2023; 146 (02) 668-677 eng.
• 19 Farrar MA, Teoh HL, Carey KA. et al. Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry 2018; 89 (09) 937-942
• 20 Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol 2022; 39: 1-10
• 21 Kim AR, Lee JM, Min YS. et al. Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: a retrospective study. Ann Indian Acad Neurol 2020; 23 (06) 796-801
• 22 Pane M, Coratti G, Sansone VA. et al. Italian EAP Working Group. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function. Eur J Neurol 2023; 30 (06) 1755-1763
• 23 Chacko A, Sly PD, Ware RS. et al. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3. Thorax 2022; 77 (01) 40-46
• 24 Gonski K, Chuang S, Teng A. et al. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience. Neuromuscul Disord 2023; 33 (06) 531-538
• 25 Tscherter A, Rüsch CT, Baumann D. et al. Swiss-Reg-NMD group. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscul Disord 2022; 32 (05) 399-409
• 26 Pontes C, Fontanet JM, Vives R. et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. Orphanet J Rare Dis 2018; 13 (01) 206
• 27 Finkel RS, Mercuri E, Meyer OH. et al. SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 2018; 28 (03) 197-207
• 28 WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl 2006; 450: 86-95
• 29 Stanojevic S, Quanjer P, Miller MR, Stocks J. The Global Lung Function Initiative: dispelling some myths of lung function test interpretation. Breathe 2013; 9 (06) 462-474
• 30 Berti B, Fanelli L, de Sanctis R. et al. Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA patients: development of a new module. J Neuromuscul Dis 2021; 8 (04) 589-601
• 31 Pitarch Castellano I, Cabrera-Serrano M, Calvo Medina R. et al. Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus). Neurologia (Engl Ed) 2022; 37 (03) 216-228
• 32 Darbà J. Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis. Orphanet J Rare Dis 2020; 15 (01) 8
• 33 Vázquez-Costa JF, Povedano M, Nascimiento-Osorio AE. et al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts' study. Eur J Neurol 2022; 29 (11) 3337-3346
• 34 Sun J, Harrington MA, Porter B. TREAT-NMD Global Registry Network for SMA. Sex difference in spinal muscular atrophy patients - are males more vulnerable?. J Neuromuscul Dis 2023; 10 (05) 847-867
• 35 van der Heul AMB, Cuppen I, Wadman RI. et al. Feeding and swallowing problems in infants with spinal muscular atrophy type 1: an observational study. J Neuromuscul Dis 2020; 7 (03) 323-330
• 36 Finkel RS, Day JW, Pascual Pascual SI. et al. DEVOTE Study Group. DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: study design and part A results. J Neuromuscul Dis 2023; 10 (05) 813-823
• 37 Luu KT, Norris DA, Gunawan R, Henry S, Geary R, Wang Y. Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations. J Clin Pharmacol 2017; 57 (08) 1031-1041
• 38 Antonaci L, Pera MC, Mercuri E. New therapies for spinal muscular atrophy: where we stand and what is next. Eur J Pediatr 2023; 182 (07) 2935-2942
• 39 Ioannidis JP. Why most clinical research is not useful. PLoS Med 2016; 13 (06) e1002049
• 40 Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol 2022; 22 (01) 287